fromilid õhukese polümeerikattega tablett
krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 500mg 14tk
fromilid õhukese polümeerikattega tablett
krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 250mg 14tk
onureg
bristol-myers squibb pharma eeig - asatsitidiin - leukeemia, müeloidne, äge - antineoplastilised ained - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
blincyto
amgen europe b.v. - blinatumomab - prekursorko-lümfoblastne leukeemia-lümfoom - antineoplastilised ained - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
optimark
mallinckrodt deutschland gmbh - gadoversetamiid - magnetresonantstomograafia - kontrastsusmeedium - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. optimark on näidustatud kasutamiseks koos magnetresonantstomograafia (mri) kesk närvisüsteem (kns) ja maksa. see annab kontrasti võimendamine ja hõlbustab visualiseerimist ja aitab iseloomustus fookuskaugus kahjustused ja ebanormaalne struktuuride kesknÄrvisÜsteemi ja maksa patsientidel, kellel on teada või väga kahtlustatakse patoloogia.
sumamed kõvakapsel
teva pharma b.v. - asitromütsiin - kõvakapsel - 250mg 6tk
azitrox 500 mg õhukese polümeerikattega tablett
zentiva k.s. - asitromütsiin - õhukese polümeerikattega tablett - 500mg 3tk
sumamed suukaudse suspensiooni pulber
teva pharma b.v. - asitromütsiin - suukaudse suspensiooni pulber - 20mg 1ml 20ml 1tk
sumamed forte suukaudse suspensiooni pulber
teva pharma b.v. - asitromütsiin - suukaudse suspensiooni pulber - 40mg 1ml 30ml 1tk; 40mg 1ml 15ml 1tk
sumamed õhukese polümeerikattega tablett
teva pharma b.v. - asitromütsiin - õhukese polümeerikattega tablett - 500mg 3tk